Editas Medicine, Inc. reported $47M of revenue over the trailing twelve months, +21% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $47M (to Q2 2026). Net income: −$74M, trailing twelve months to Q2 2026. Free cash flow: −$121M, trailing twelve months to Q2 2026. Operating margin: −349%, trailing twelve months to Q2 2026.

EDITEditas Medicine, Inc.

Healthcare

$2.83-28% 1Y

$2.83

$1.6652 weeks$4.15

EDIT as reported

Editas Medicine, Inc. reported $47M of revenue over the trailing twelve months, +21% on the year before. 9 reported series are charted on this page, each one as filed.

$47M

Revenue, trailing twelve months · to Q2 2026 · +21% against the twelve months before

Net income: −$74M
Net income · −69% year on year · trailing twelve months to Q2 2026
Free cash flow: −$121M
Free cash flow · −41% year on year · trailing twelve months to Q2 2026
Operating margin: −349%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EDIT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$47M	+21%	Q2 2026
Net income	−$74M	−69%	Q2 2026
EPS	−$0.69	−76%	Q2 2026
Operating margin	−349%	n/a	Q2 2026
Net margin	−348%	n/a	Q2 2026
ROE	−1153%	n/a	Q2 2026
ROA	−72%	n/a	Q2 2026
ROIC	157%	n/a	Q2 2026
Free cash flow	−$121M	−41%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.